Genmab — Maj 2019
-
Tjah..hvis MAIA ikke bliver godkendt....så er det her ren børnhave ved siden af..
-
med eller uden pædagoger..:-D
-
If you invest in the ADSs in this offering, your interest will be immediately diluted to the extent of the difference between the initial public offering price per ADS in this offering and the net book value per ADS after this offering. Dilution results from the fact that the initial public offering price per ADS is substantially in excess of the net book value per ADS. As of March 31, 2019, we had a historical net book value per ADS of $1.88, or DKK 124.85 per share ($18.79).
-
Måske en eller anden er i stand til at få noget ud af side 79: https://www.sec.gov/Archives/edgar/data/1434265/000104746919003334/a2238822zf-1.htm
-
Vores Q&A med Zealand Pharma i eftermiddags: http://www.proinvestor.com/chathistory/-99/q&a zealand pharma 2019-05-29
-
Tak for indsatsen.

-
Med 7 mia på bogen + stigende royalty + resterende milestones giver det i min optik ikke mening at udvide kapitalen med yderligere 3 mia når de samtidig ”kun” går efter 50/50 deals på de næste to kandidater i pip’en. Det bliver sammen med en eller flere partnere til over 20 mia kr der kan investeres. Det er helt ude i skoven. Der må ligge noget andet til grund for det her.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind